Current Clinical Trials Available for Enrollment:
a trial is available for anyone over the age of 50 that has subfoveal cnv lesions secondary to amd. the purpose of this study is to evaluate the safety and efficacy of conbercept ivt compared to aflibercept in patients with wet amd. total study duration is 96 weeks
Glaucoma Clinical Trial
A trial is available for anyone over the age of 18 with OAG or OHT. The purpose of this study is to control glaucoma by injecting sustained release Bimatoprost into the anterior chamber about every 4 months compared to Selective Laser Trabeculoplasty, or SLT. Total study duration is 1 year
Retinal Vein Occlusion
a trial is available for anyone over the age of 18 with rvo to demonstrate that sc cls-ta in conjunction with ivt aflibercept is superior to ivt aflibercept alone. total study duration is 48 weeks
Geographic Atrophy secondary to AMD
a trial is available for anyone over the age of 50 to asses efficacy and safety of intravitreous administration of zimura for geographic atrophy. total study duration is 18 months
AdenoVitral and Bacterial Conjunctivitis
A trial is available for anyone with conjunctivitis. The purpose of this study is to treat conjunctivitis with Iodine and Dexamethasone ophthalmic suspension. Total study duration is 13 days
Studies on the horizon:
diabetic macular edema • ptosis • pain and inflammation post cataract • biosimilar medication for amd • mebomian gland • biosimilar medication for dme
Special thanks to those who have participated in prior studies.
For those of you who have recently participated, thank you for helping us with recent approvals of:
eylea for wet macular degeneration and crvo • lucentis and OZURDEX for diabetic macular edema • omidria for cataract surgery • zioptan and simbrinza for glaucoma
If you have any questions about clinical research at East Florida Eye Institute, or are interested in participating in a clinical trial, please fill out the form below.
You may also submit your contact information and diagnosis if you would like to be contacted for a future clinical trial.